Eric L Reese
Vice President of Sales & Marketing, SensiQ Technologies Inc., USA
Title: The next step in SPR-based fragment screening
Biography
Biography: Eric L Reese
Abstract
SensíQ’s patented gradient injection methods provides KD’s from single injections, allowing SensiQ instruments to eliminate secondary screens such as one competitor’s “Affinity Screen”. No other SPR providers have gradient injection technology. SensiQ Pioneer FE customers have demonstrated that a combination of excellent sensitivity, OneStep® gradient injections and the integrated Active Selection software provides superior results over other SPR suppliers. Now SensíQ has developed a new binding competition assay method for rapidly screening fragments, NeXtStep. Like OneStep®, NeXtStep enables full kinetic analysis in single competition injection and competition is clearly seen as a lack of binding in the presence of the competitor. Taken together, OneStep® and NeXtStep enable straightforward fragment screening workflow optimization and thus a faster drug discovery process